Japan Digestive Disease Week 2025
International Poster Session13 (JDDW)
October 31, 15:20–16:00, Room 15 (Kobe International Exhibition Hall No.1 Building Digital Poster Venue)
IP-61_E
EUS-guided portal pressure gradient measurement: clinical usefulness
- 1
- Virgen Macarena Hospital
AIMS We report our experience on EUS-guided portal pressure gradient measurement (EUS-PPGm).
METHODS Prospective study of patients referred for EUS-PPGm. A 25G dedicated needle was used.
RESULTS The procedure was performed in 68 patients.
Indications: Assessment of metabolic associated steatotic liver disease in morbid obese patients: 43. Portal hypertension (PH): 20. Evaluation for curative therapy in hepatocellular carcinoma (HCC): 3. Acute response to intravenous propranolol: 2.
Fifty (73,5%) EUS-guided bilobar liver biopsies (EUS-BLB), 3 band ligation for esophageal varices and 1 EUS-guided coil therapy were also performed in the same endoscopic session.
EUS-PPGm was successfully obtained in 61/68 patients (90%). In 12/43 cases of morbid obese patients (28%) the EUS-PPGM was >6 mmHg patients without varices nor fibrosis on EUS-BLB. Patients were treated accordingly with the results of EUS-PPGm. There was observed a significant reduction of PPG in one patient treated with intravenous propranolol.
Mean time to obtain EUS-PPGm 23 minutes. Three adverse events were observed. One mild epigastric pain 2 day after a combined procedure, one self-limited bleeding from the cardias and one atrial fibrillation.
CONCLUSIONS EUS-PPGm, even combined with EUS-BLB, seems safe, providing relevant clinical information. A notewhorty proportion of morbid obese patients were precociously diagnosed of portal hypertension in early reversible stages by EUS-PPGm.
METHODS Prospective study of patients referred for EUS-PPGm. A 25G dedicated needle was used.
RESULTS The procedure was performed in 68 patients.
Indications: Assessment of metabolic associated steatotic liver disease in morbid obese patients: 43. Portal hypertension (PH): 20. Evaluation for curative therapy in hepatocellular carcinoma (HCC): 3. Acute response to intravenous propranolol: 2.
Fifty (73,5%) EUS-guided bilobar liver biopsies (EUS-BLB), 3 band ligation for esophageal varices and 1 EUS-guided coil therapy were also performed in the same endoscopic session.
EUS-PPGm was successfully obtained in 61/68 patients (90%). In 12/43 cases of morbid obese patients (28%) the EUS-PPGM was >6 mmHg patients without varices nor fibrosis on EUS-BLB. Patients were treated accordingly with the results of EUS-PPGm. There was observed a significant reduction of PPG in one patient treated with intravenous propranolol.
Mean time to obtain EUS-PPGm 23 minutes. Three adverse events were observed. One mild epigastric pain 2 day after a combined procedure, one self-limited bleeding from the cardias and one atrial fibrillation.
CONCLUSIONS EUS-PPGm, even combined with EUS-BLB, seems safe, providing relevant clinical information. A notewhorty proportion of morbid obese patients were precociously diagnosed of portal hypertension in early reversible stages by EUS-PPGm.
- Index Term 1: Portal hypertension
- Index Term 2: EUS-guided portal pressure gradient